DGFT Begins Anti-Dumping Probe on Sulphenamides Imports from China, EU, USA

In a response to allegations that the country's domestic industry has suffered a material injury due to unreasonably low prices at which imports of sulphenamides accelerators from China, the European Union, and the United States are being sold, DGTR has initiated an anti-dumping probe into these items.

A sulphenamide accelerator is commonly used as an additive in pharmaceutical research aimed at enhancing drug viability, especially in the development of antibacterial agents. The investigation will assess whether these imports are damaging the domestic market and, if so, whether anti-dumping duties should be imposed.

The DGTR had invited all interested parties, including exporters, importers, and domestic producers, to send their comments and support views on additional Product Control Numbers (PCNs) in 15 days after the notification.

Joint Director (FT) Rajiv Kumar Soni confirmed that the timelines to submit the Exporter's, Importer's and Unrelated Importer's Questionnaire Responses were extended to March 22, 2025, following the request received.

Before the Directorate General of Trade Remedies, the case registered as AD (01) - 49/2024 was initiated due to a plea filed by NOCIL Ltd claims that dumped imports have substantially executed injuries to India. DGTR verifies from the said claim that under the Customs Tariff Act, 1975 and respective anti-dumping rules, it would assess if these imports were indeed undercutting domestic production.

As per preliminary findings, domestically produced sulphenamides accelerators and imported sulphenamides accelerators were comparable in chemical characteristics, method of manufacture, and commercial use. Primarily led by NABIL Limited, which held a sizeable investment into domestic production with its standing of support from Finorchem Limited, DGTR acknowledges that NOCIL stands as a domestic industry under Rule 2(b) of the Anti-Dumping Rules.